報價延遲最少15分鐘:2026/04/15 09:30 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.09 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.53/-0.28
|
|
企業價值
1.27B
|
| 資產負債 |
|
每股賬面淨值
0.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). |
